MD 240928 and harmaline: Opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice

Ray W. Fuller, Conrad J. Wong, Susan K. Hemrick-Luecke

Research output: Contribution to journalArticle

Abstract

In mice treated 24 hrs earlier with pargyline (20 mg/kg i.p), both type A and type B monoamine oxidase (MAO-A and MAO-B) were partially inactivated in brain, heart and liver. The abilities of two short-acting, reversible inhibitors of MAO to antagonize that inactivation were compared. Pretreatment with MD 240928 at doses of 10, 20 or 30 mg/kg i.p. antagonized the inactivation of type B MAO but did not alter the inactivation of type A MAO in all three tissues. In contrast, pretreatment with harmaline at a dose of 10 mg/kg i.p. antagonized the inactivation of type A MAO but did not alter the inactivation of type B MAO. Antagonism of the pargyline-induced inactivation is interpreted as being due to the transient selective inhibition of MAO-A by harmaline and of MAO-B by MD 240928, preventing the mechanism-based inactivation of those enzymes by pargyline. The selective protection by harmaline is in agreement with earlier results with that compound in rats; the selective protection by MD 240928 is the first report of selective protection against MAO-B inactivation.

Original languageEnglish (US)
Pages (from-to)409-412
Number of pages4
JournalLife Sciences
Volume38
Issue number5
DOIs
StatePublished - Feb 3 1986

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'MD 240928 and harmaline: Opposite selectivity in antagonism of the inactivation of types A and B monoamine oxidase by pargyline in mice'. Together they form a unique fingerprint.

  • Cite this